Packing Information

Pcs/Carton: N/A

Packing Size/Carton:N/A

Packing Vol/Carton: N/A

N.W./Carton: N/A

G.W./Carton: N/A

QTY in 40HQ: N/A

QTY in 40GP: N/A

QTY in 20GP: N/A

Packaging: 25 kg/drum

Model: 12-2

Appearance: White powder

Heavy Metals: 0.1 ppm

CAS No.: 474-25-9

Synonyms: Chenodeoxycholic acid, Deoxycholic acid

Purity: 90%

Applications: Intermediate for Ursodeoxycholic acid; Intermediate for Obeticholic acid

English Name: Chenodeoxycholic acid

CAS No.: 474-25-9

Molecular Formula: C24H40O4

Molecular Weight: 392.57

EINECS No.: 207-481-8

Chemical Properties: This product is extracted from the bile of chickens, ducks, geese, and similar animals. It appears as a white or pale yellow crystalline powder. Uses: This product serves as a dissolution agent for cholesterol gallstones. It is primarily used for the prevention and treatment of cholesterol gallstone disease. Action: This product is currently one of the most widely used medications globally for the treatment of gallstones; it also serves as a raw material for the synthesis of Ursodeoxycholic acid (UDCA) and other steroidal compounds.

Chenodeoxycholic Acid (CDCA): Comprehensive Actions and Uses

I. Core Pharmacological Actions

1.    Dissolution of Cholesterol Gallstones

It reduces cholesterol saturation in bile, gradually dissolving cholesterol crystals and gallstones, and minimizes the precipitation of biliary cholesterol, thereby preventing stone enlargement and recurrence at the source.

2.    Regulation of Biliary Metabolism; Cholagogic and Hepatoprotective Effects

It promotes the normal secretion and excretion of bile, clears the biliary tract, and alleviates bile stasis; it protects hepatocytes, improves hepatic and biliary microcirculation, and relieves symptoms associated with "damp-heat" in the liver and gallbladder—such as a bitter taste in the mouth and distending pain in the hypochondriac region.

3.    Anti-inflammatory + Protection of Biliary Mucosa

It reduces chronic inflammation in the biliary tract and intestines, repairs damage to the bile duct mucosa, and lowers the incidence of acute attacks of cholecystitis and cholangitis.

4.    Regulation of Lipid Metabolism

It inhibits hepatic cholesterol synthesis, assists in regulating blood lipids, and helps correct hyperlipidemic metabolic disorders.

5.    Conversion into Bile Acid Precursors

Within the body, it can be metabolized into 7-ketolithocholic acid and Ursodeoxycholic acid (UDCA), which act synergistically to exert hepatoprotective and anti-stasis effects.

II. Main Clinical Indications / Therapeutic Uses

1.    Gallstones

Primarily indicated for cholesterol-type gallstones (specifically in patients with stones of small to moderate size and intact gallbladder function), for use in conservative stone dissolution therapy and for the prevention of recurrence following surgical intervention. 2. Cholestatic Liver Diseases

Adjunctive treatment for chronic hepatitis, primary biliary cholangitis, drug-induced liver injury, and cholestasis syndromes.

3. Biliary Tract Disorders

Chronic cholecystitis, biliary dyspepsia, and fat malabsorption (characterized by abdominal distension and diarrhea following the consumption of fatty foods).

4. Industrial / Pharmaceutical Raw Material Applications

It serves as a core industrial raw material for the synthesis of Ursodeoxycholic Acid (UDCA), as well as a key active ingredient in porcine bile powder and various animal bile extracts.

III. Comparative Overview (Simplified)

• Chenodeoxycholic Acid (CDCA): Primarily focused on gallstone dissolution; provides basic choleretic effects.

• Ursodeoxycholic Acid (UDCA): Offers superior hepatoprotective effects with fewer side effects; more widely utilized in the clinical management of liver diseases.